Level I PD-MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia

dc.contributor.authorBoel, Judith A
dc.contributor.authorMDS Study Group Mild Cognitive Impairment in Parkinson's Disease
dc.contributor.authorde Bie, Rob M A
dc.contributor.authorSchmand, Ben A
dc.contributor.authorDalrymple-Alford, John C
dc.contributor.authorMarras, Connie
dc.contributor.authorAdler, Charles H
dc.contributor.authorGoldman, Jennifer G
dc.contributor.authorTröster, Alexander I
dc.contributor.authorBurn, David J
dc.contributor.authorLitvan, Irene
dc.contributor.authorGeurtsen, Gert J
dc.date.accessioned2026-01-13T13:15:19Z
dc.date.available2026-01-13T13:15:19Z
dc.date.issued2022-04-29
dc.date.updated2026-01-13T13:15:20Z
dc.description.abstractBackground: The criteria for PD-MCI allow the use of global cognitive tests. Their predictive value for conversion from PD-MCI to PDD, especially compared to comprehensive neuropsychological assessment, is unknown. Methods: The MDS PD-MCI Study Group combined four datasets containing global cognitive tests as well as a comprehensive neuropsychological assessment to define PD-MCI (n = 467). Risk for developing PDD was examined using a Cox model. Global cognitive tests were compared to neuropsychological test batteries (Level I&II) in determining risk for PDD. Results: PD-MCI based on a global cognitive test (MMSE or MoCA) increases the hazard for developing PDD (respectively HR = 2.57, P = 0.001; HR = 4.14, P = <0.001). The C-statistics for MMSE (0.72) and MoCA (0.70) were lower than those based on neuropsychological tests (Level I = 0.82; Level II = 0.81). Sensitivity, specificity and diagnostic accuracy balance was best in Level II. Conclusion: MMSE and MoCA predict conversion to PDD. However, Level II neuropsychological assessment seems the preferred assessment for PD-MCI.
dc.format.extent5 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec725322
dc.identifier.issn0885-3185
dc.identifier.pmid35582313
dc.identifier.urihttps://hdl.handle.net/2445/225369
dc.language.isoeng
dc.publisherWiley
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1002/mdc3.13451
dc.relation.ispartofMovement Disorders, 2022, vol. 9, num.4, p. 479-483
dc.relation.urihttps://doi.org/10.1002/mdc3.13451
dc.rightscc by (c) Boel, Judith A et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.classificationMalaltia de Parkinson
dc.subject.classificationDemència
dc.subject.classificationDiagnòstic
dc.subject.otherParkinson's disease
dc.subject.otherDementia
dc.subject.otherDiagnosis
dc.titleLevel I PD-MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
252371.pdf
Mida:
210.72 KB
Format:
Adobe Portable Document Format